The occupational exposure of 21 nurses and pharmacy personnel from eight hospitals to cyclophosphamide and ifosfamide was determined by quantifying the amount of the drugs handled and by measuring the urinary excretion of the unmetabolised substances. Preparing antineoplastic drugs for intravenous treatment was the major task of all study participants. Twenty four hour urine was collected on days when cyclophosphamide andlor ifosfamide were mixed, on average 3900 mg cyclophosphamide and/or 5900 mg ifosfamide. The analyses were performed by gas chromatography with electron capture, detection limit 2' p5g124 hour urine. Despite standard safety precautions, including a vertical laminar air flow safety cabinet and gloves, cyclophosphamide was detected in 12 of 31 and ifosfamide in four of 21 urine samples on days when the drugs were handled. Excretion of cyclophosphamide ranged from 3*5 to 38 og124 h (mean ,ug/24 h) urine, ifosfamide from 5 to 12-7 ug/24 h (mean 9 ug/24 h) urine. Based on an excretion rate of 11'3% unmetabolised cyclophosphamide, the average amount excreted corresponded to an uptake of 101 pg cyclophosphamide. For ifosfamide the mean quantity incorporated was 20 pg assuming that 45% of the drug was excreted. Pertaining to the doses handled, the uptake of cyclophosphamide and ifosfamide was estimated to be approximately 0*0025% and 0-0004% respectively.
Abstract
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Despite time-consuming purification procedures, gas chromatographic analysis is a suitable method for monitoring personnel occupationally exposed to cyclophosphamide and ifosfamide and is a major contribution to the evaluation of potential health risks of exposed personnel.
(Occup Environ Med 1994;51:229-233)
The amount of antineoplastic drugs employed for treatment of malignant diseases is constantly increasing. Diverse chemical substances capable of inhibiting tumour growth are known. Many chemotherapeutic agents are carcinogenic in animals-for example, dacarbazine and cyclophosphamide.' Of these, cyclophosphamide is judged to be a human carcinogen.'-5 Also, it is known to have mutagenic and teratogenic effects.
It is of increasing concern that professional personnel involved in the preparation and administration of antineoplastic drugs are occupationally exposed to these substances. Various safety measures have been introduced in the past and handling practices have been improved, although these are not generally standard. 6 Recently, in many hospitals the task of preparing antineoplastic drugs has been restricted to a separate room usually installed in the hospital pharmacy. Here, specially trained personnel (nurses, medical or pharmacy technicians, pharmacists) are responsible for the preparation of antineoplastic drugs for all hospital wards. Consequently, these workers face a cumulative exposure.
The purpose of this study was to quantify the exposure by measuring the excretion of cyclophosphamide and ifosfamide in the urine of employees regularly handling these agents in hospital pharmacies. Emphasis was given to the exact amount of antineoplastic drugs mixed. Cyclophosphamide and ifosfamide were chosen as a substantial proportion of both drugs is excreted in urine unmetabolised.7-9 Furthermore, these substances are considered representative of commonly used antineoplastic drugs and their pharmacokinetic properties are well studied.8 10 The detection of cyclophosphamide and ifosfamide was performed by gas chromatography with electron capture. Before gas chromatographic analysis 200 ml of urine was purified as described by Evelo et al '2 and Hirst et al."3 The final sample was dissolved in 100 lul isooctane.
Subjects and methods

GAS CHROMATOGRAPHIC ANALYSIS
Each sample (1 pl) was injected into a Shimadzu gas chromatograph. An OV-1 column was used with a nitrogen flow of 27 ml/min. The injection temperature was 300°C. The initial temperature of 190°C was increased after two minutes by 8°/min to 230°C for 10 minutes and then raised by 10°/min to 280°C for 25 minutes to clean the column. The retention times of trifluoracetic acid derivates from cyclophosphamide and ifosfamide were 8-7 and 7-4 minutes respectively. The detection limit for cyclophosphamide and ifosfamide was 2-5 ,ug/24 h urine.
As internal standards 10 pg cyclophosphamide or ifosfamide were added to 200 ml urine unless both drugs were handled on the day of urine collection. The recovery rates for cyclophosphamide and ifosfamide were determined by spiking urine from an unexposed person with 200 pg cyclophosphamide or ifosfamide per 200 ml urine. The extraction recovery was 40 4 (2-74)% (n = 4) and 80-6 (7-66)% (n = 4), respectively. The calculation of the final urinary excretion of cyclophosphamide and ifosfamide was based on these recovery rates. Urinary creatinine was determined in each sample.
Due to impurities in the urine 10 of 41 cyclophosphamide samples and one of 22 ifosfamide samples could not be analysed.
The percentage of unmetabolised cyclophosphamide and ifosfamide excreted was determined by analysing 24 hour urine of patients treated intravenously with either drug (1 1-3% and 45%, respectively).
STATISTICS
The statistical calculations were performed with SPSS software comprising regression analysis and Mann-Whimey tests. Results are presented as means (SD).
Results
The working conditions differed slightly among the hospitals with respect to glove thickness, the use of protective clothing, frequency of waste disposal, and daily work Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs Pertaining to the doses handled, the uptake of cyclophosphamide or ifosfamide was estimated to be approximately 0-0025% and 0 0004% respectively.
The amount of cyclophosphamide and ifosfamide excreted was of the same magnitude, but cyclophosphamide was found more often than ifosfamide. This is possibly due to the fact that cyclophosphamide is not as readily soluble in an aqueous solvent compared with ifosfamide, resulting in a longer handling time. Also, differences in the drug resorption and the higher number of cyclophosphamide preparations could have contributed to this finding. Neither of the substances was measured in urine from hospital personnel who collected urine one to two days after handling cyclophosphamide or ifosfamide. This finding is in agreement with the pharmacokinetic properties of both substances. 10 The amount of cyclophosphamide or ifosfamide excreted did not relate to the dose or number of drug preparations on the day of urine collection or to the two days before urine collection. Similar findings have been reported." 12 The number of ampoules used per preparation remains unknown. This could be of importance as the insertion of a needle into the ampoule to add fluid for dissolving the substance is a critical moment.
Furthermore, no significant correlation was seen between age, duration of exposure to cytostatic agents, drug intake, and the detection of cyclophosphamide or ifosfamide. Cyclophosphamide was found in the urine of only one male participant. The influence of sex on cyclophosphamide uptake, metabolism, and excretion has been discussed'2 13 but remains unclear due to the limited number of samples from male study participants.
Few investigations on biological monitoring of hospital personnel exposed to cytostatic drugs exist and the exposure is poorly quantified. Hirst et al reported on two nurses handling 0-8-2-6 g cyclophosphamide without protective clothing."2 A maximum of 9 #ug cyclophosphamide was measured in urine. Despite regular safety precautions, Evelo et al and Sessink et al were able to measure up to 2-5 jug cyclophosphamide in the urine of occupationally exposed personnel." 13 Pethran et al detected 3-35 ug cyclophosphamide in the urine of a nurse who handled 500 mg cyclophosphamide without glove protection. '4 In comparison with our study group the dosage handled was considerably lower. We are not aware of any results on biological monitoring of workers exposed to ifosfamide.
Cytostatic Before discussing studies concerning the induction of second primary tumours after chemotherapy it needs to be emphasised that the doses of cyclophosphamide and ifosfamide absorbed by our study participants were 1 04 to 1 0-5 times smaller than the usual therapeutic doses that are given repeatedly intraveneously. Haas et al calculated a relative risk for acute leukaemia after treatment of ovarian or breast cancer with cyclophosphamide of 14-6 and 2-7, respectively.4 After an 11 year follow up of patients with rheumatoid arthritis treated with 50-150 mg cyclophosphamide, the relative risk for the development of malignancy was determined to be 2-3.2 By comparison with these data, the potential risk after absorption of the observed trace amounts of cyclophosphamide and ifosfamide in our study group seems minute.
In summary, to date it remains difficult to estimate the potential health risk for hospital personnel involved in the preparation of cytostatic agents for patient therapy. Measurement of the excretion of these drugs in urine as an indicator of incorporation, is, however, a valuable index for the evaluation of the actual exposure. Thus the data presented here contribute greatly to the estimation of the potential hazards of personnel regularly handling antineoplastic drugs under standard safety precautions. 
